Clinical trials: No-Reflow Phenomenon
Myocardial Infarction, No-Reflow Phenomenon
Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI
The patients with acute myocardial infarction (AMI) present high mortality and morbidity rate,even treated with stenting in the blocked heart vessels. The appearance of no-reflow is common after re-opening of the blocked vessel.
- Trial name
- NCT02233790
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 600 people
- Sponsor
- First Hospital of China Medical University
ST Segment Elevation Myocardial Infarction (STEMI), No Reflow Phenomenon
The Investigator Administers Intracoronary Adrenaline Via the Catheter in STEMI Patients During Primary PCI, After Flow Restoration and Before Stenting, and Studies Its Effect in Prevention of No Reflow
The aim of this work is to study the role of intracoronary adrenaline administration as a preventive tool for no reflow in patients undergoing primary PCI.
- Trial name
- NCT06847568
- Testing
- Adrenaline
- Where
- Egypt
- Volunteers
- 1,000 people
- Sponsor
- Ain Shams University
Myocardial Infarction, Percutaneous Coronary Intervention
Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
The purpose of this study is to determine whether intracoronary selective thrombolysis are more effective than tirofiban on the coronary flow during primary percutaneous coronary intervention for the acute myocardial infarction.
- Conditions
- Myocardial Infarction, Percutaneous Coronary Intervention, Thrombolytic Therapy
- Trial name
- ERUPTION (NCT02131220)
- Testing
- Prourokinase, Tirofiban, normal saline
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Fudan University
Coronary Arteriosclerosis, Coronary Heart Disease
Analysis of Human Coronary Aspirate
During elective percutaneous coronary intervention (PCI), both proximal and distal protection devices are used. The distal occlusion protection device temporarily occludes the vessel distal to the lesion during the intervention…
- Conditions
- Coronary Arteriosclerosis, Coronary Heart Disease, No Reflow Phenomenon
- Trial name
- AHCA (NCT01430884)
- Testing
- Aspirated Coronary Blood
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Universität Duisburg-Essen
STEMI, Large Thrombus Burden
Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction
Angiographic no-reflow during primary PCI procedures occurs at relatively high rate (25%) and is associated with worsening of long term morbidity and mortality.
- Conditions
- STEMI, Large Thrombus Burden, No-Reflow Phenomenon
- Trial name
- UPFRONT-STEMI (NCT05393557)
- Testing
- Upfront preparation of microcirculation to minimize risks of no-reflow and reperfusion injury
- Volunteers
- 626 people
- Sponsor
- Cairo University
Myocardial Infarction
THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction
The occurrence of no-reflow phenomenon after recanalization of the infarct related artery in acute myocardial infarction is described in up to 40% of cases.
- Trial name
- REOPEN-AMI (NCT00590070)
- Testing
- adenosine, nitroprusside
- Where
- Italy
- Volunteers
- 240 people
- Sponsor
- Catholic University of the Sacred Heart
Myocardial Infarction
THE LASER-AMI STUDY - Excimer Laser Versus Manual Thrombus Aspiration in Acute Myocardial Infarction
The occurrence of no-reflow phenomenon after recanalization of the infarct related artery in acute myocardial infarction is described in up to 40% of cases.
- Trial name
- LASER-AMI (NCT01826006)
- Testing
- Excimer laser, Manual Thrombus Aspiration
- Where
- Italy
- Volunteers
- 194 people
- Sponsor
- Catholic University of the Sacred Heart
No-Reflow Phenomenon, STEMI - ST Elevation Myocardial Infarction
NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction
The aim of this study is to investigate the association between NGAL plasma levels in ST-elevation myocardial infarction and the no-reflow phenomenon, adverse events during hospitalization and at 30-day follow-up.
- Trial name
- NCT03264859
- Testing
- NGAL levels early and post STEMI
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
No-Reflow Phenomenon
the No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention (PCI)
1- to find metabolic factors that correlate with the development of no reflow phenomenon that may help prevent its occurrence .
- Trial name
- NCT04835974
- Testing
- 1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assiut University
No-Reflow Phenomenon
Alpha Lipoic Acid Effect on No-Reflow Phenomenon
Prospective, randomized, open-label, controlled clinical trial to evaluate the efficacy and tolerability of Alpha Lipoic Acid administration on oxidative stress, inflammatory markers, clinical outcome and occurrence of No-Reflow…
- Trial name
- NCT05360602
- Testing
- Alpha Lipoic Acid plus the standard care for post-PCI MI, The standard care for post-PCI MI
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
Reperfusion Injury, Myocardial
Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI
This study is a single-center, prospective controlled trial addressing effectiveness of empagliflozin on cardiac-renal injury in patients with STEMI.
- Trial name
- NCT03591991
- Testing
- Empagliflozin
- Volunteers
- 128 people
- Sponsor
- Chinese PLA General Hospital
STEMI, No-Reflow Phenomenon
Empagliflozin for No-reflow Phenomenon in PCI for STEMI
Myocardial infarction remains, in our current era, a leading cause of morbidity and mortality both domestically and globally. A significant contributor to this issue is reperfusion injury, which enlarges the infarction…
- Trial name
- EMPA-PCI (NCT06342141)
- Testing
- Empagliflozin 25 milgrams (Mg), Empagliflozin 10 Mg
- Where
- Mexico
- Volunteers
- 162 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
No Reflow Phenomenon, Anterior STEMI
Oral Nicorandil for Prevention of No Reflow Phenomenon in Anterior STEMI Patients Undergoing PPCI
Aim of the study is to Investigate the potential role of oral nicorandil in preventing the No reflow phenomenon in anterior ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention…
- Trial name
- NCT07138508
- Testing
- Nicorandil 20mg
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Ain Shams University
ST-Segment Elevation Myocardial Infarction (STEMI), No-Reflow Phenomenon
Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention
Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.
- Conditions
- ST-Segment Elevation Myocardial Infarction (STEMI), No-Reflow Phenomenon, Coronary Slow Flow, Acute Myocardial Infarction
- Trial name
- AMPACT (NCT07536802)
- Testing
- Adenosine pre-medication, Standard care
- Where
- 2 sites in Pakistan
- Volunteers
- 1,148 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
Myocardial Infarction, No Reflow Phenomenon
Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI
To evaluate the diagnostic value of the selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with STEMI undergoing primary PCI.
- Trial name
- VaBiNoR (NCT07132489)
- Testing
- HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio
- Volunteers
- 114 people
- Sponsor
- Assiut University
Acute Coronary Syndrome, No-Reflow Phenomenon
Adrenaline for the Treatment of No-Reflow in Normotensive Patients
No-reflow is defined as the lack of myocardial perfusion despite opening of the epicardial coronary vessels in the setting of percutaneous coronary intervention (PCI).
- Conditions
- Acute Coronary Syndrome, No-Reflow Phenomenon, Normotensive
- Trial name
- NCT04699110
- Testing
- Adrenaline, Adenosine
- Where
- Pakistan
- Volunteers
- 201 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
Myocardial Infarction
Nitroprusside for Prevention of no-Reflow in Primary Angioplasty
In patients admitted with acute myocardial infarction, there is a total occlusion of a coronary artery. Even after emergency catheterization and angioplasty, in some patients, the resumed blood flow is suboptimal and impacts on…
- Trial name
- NCT00128791
- Testing
- Nitroprusside
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Soroka University Medical Center
No-Reflow Phenomenon, Coronary Artery Disease
A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease
The aim of this study was to determine the effect of intra-coronary administration of nicorandil on the prevention of lowering of coronary blood flow for high-risk plaque lesions defined as the high value of lipid core burden…
- Conditions
- No-Reflow Phenomenon, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- NCT05427786
- Testing
- Nicorandil
- Where
- South Korea
- Volunteers
- 458 people
- Sponsor
- Korea University Anam Hospital
Myocardial Infarction, No-Reflow Phenomenon
Genetic Determinants of the Coronary Microvascular Obstruction in PCI
Myocardial infarction (MI) remains one of the most common causes of death. Percutaneous coronary intervention (PCI) is the main treatment option to restore blood flow through the infarction-related coronary artery (IRA) in MI…
- Trial name
- NCT05355532
- Testing
- different variants of SNPs that may be associated with the coronary microvascular obstruction development
- Where
- 2 sites in Russia
- Volunteers
- 80 people
- Sponsor
- Privolzhsky Research Medical University
Coronary Angiography, Coronary Artery Disease
Assessment Of Total Coronary Circulation Time Using TIMI Frame Count Method (TCCT-TIMI)
The aim of this study is to evaluate and describe the total coronary circulation time (TCCT) by using TIMI frame count method in patients performed coronary angiography.
- Conditions
- Coronary Angiography, Coronary Artery Disease, Coronary Artery Ectasia, Slow-Flow Phenomenon
- Trial name
- TCCT-TIMI (NCT02818127)
- Testing
- coronary angiography
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 2,000 people
- Sponsor
- Vascular and Molecular Cardiology Society